Moonshot: Inside Pfizer\'s Nine-Month Race to Make the Impossible Possible - Albert Bourla

Descriere YEO:

Moonshot: Inside Pfizer\'s Nine-Month Race - Disponibil la libris.ro

Pe YEO găsești Moonshot: Inside Pfizer\'s Nine-Month Race de la Albert Bourla, în categoria Business & Economics.

Indiferent de nevoile tale, Moonshot: Inside Pfizer\'s Nine-Month Race to Make the Impossible Possible - Albert Bourla din categoria Business & Economics îți poate aduce un echilibru perfect între calitate și preț, cu avantaje practice și moderne.

Preț: 167.35 Lei

Caracteristicile produsului Moonshot: Inside Pfizer\'s Nine-Month Race

• Brand: Albert Bourla
• Categoria: Business & Economics
• Magazin: libris.ro
• Ultima actualizare: 13-11-2024 01:34:21

Comandă Moonshot: Inside Pfizer\'s Nine-Month Race Online, Simplu și Rapid

Prin intermediul platformei YEO, poți comanda Moonshot: Inside Pfizer\'s Nine-Month Race de la libris.ro rapid și în siguranță. Bucură-te de o experiență de cumpărături online optimizată și descoperă cele mai bune oferte actualizate constant.

Descriere magazin:
Bourla, Albert: - Dr. Albert Bourla became the CEO of Pfizer in January 2019. He began his career at the company in 1993, in the Animal Health Division as technical director of Greece, and has served in numerous executive positions within the company, including COO, Group President of Pfizer Innovative Health, and Group President of Pfizer\'s Global Vaccines, Oncology, and Consumer Healthcare business. He is a doctor of veterinary medicine and holds a PhD in the Biotechnology of Reproduction from the Veterinary School of Aristotle University. In addition to his responsibilities at Pfizer, Dr. Bourla is on the executive committee of The Partnership for New York City; a director on multiple boards, including Pfizer Inc., PhRMA, and Catalyst; a Trustee of the United States Council for International Business; and a member of the Business Roundtable and the Business Council. In 2020, Dr. Bourla was named America\'s top CEO in the pharmaceuticals sector by Institutional Investor magazine.